- 211studies in the library match, of 29,380
- 84name it in the title
- 2015–2026years published
- 203peer-reviewed articles
The query: title or abstract mentions "aducanumab", "Aduhelm" or "BIIB037", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,380 study records, as of 2026-11-08. Every count on this page comes from that match. The matched list as JSON.
Aducanumab is a monoclonal antibody that binds aggregated amyloid-beta. Its two phase 3 trials were stopped early for futility and then reanalysed; one showed a benefit at the high dose and the other did not, and the approval that followed under the FDA's accelerated pathway was widely debated. The manufacturer discontinued it.
Papers on aducanumab are as much about regulation, evidence standards and cost as about the drug itself, and the counts below reflect that.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 211 matched records are quoted; each links to its study page and from there to the paper.
“Results At 6, 12, and 18 months, AP clearance was achieved in 37.9%, 70.0%, and 76.8%, respectively, of donanemab-treated participants versus 1.6%, 24.6%, and 43.1% of aducanumab-treated participants (P < 0.001).”
“SUCRA values showed that aducanumab (87.01% and 99.37%, respectively) was the most likely to achieve the best therapeutic effect based on the changes of Mini-Mental State Examination (MMSE) and Clinical Dementia Rating scale Sum of Boxes (CDR-SB) scores.”
“HIGHLIGHTS: CSF biomarkers and amyloid PET concordance were assessed in Ph3 aducanumab trials.”
“Design EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease.”
“Results Potential DMT candidates at Butler MAP (n = 50), primarily diagnosed with mild cognitive impairment (n = 29 [58%]) or mild dementia (21 [42%]), were predominantly Aβ-positive (38 [76%]), and half (25 [50%]) were subsequently treated with aducanumab.”
“Apolipoprotein E (ApoE) ε4 genotype was the main risk factor for both ARIA types; ARIA-E incidence was further associated with treatment dose, affecting the 55% of ApoE ε4 carriers in the high-dose aducanumab treatment group.”
“In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker.”
“Aducanumab resulted in a decrease of -0.39 (-22%).”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 14 |
| Randomised controlled trial | 1 |
| Other clinical trial | 29 |
| Cohort or longitudinal study | 6 |
| Case-control study | 1 |
| Cross-sectional study | 2 |
| Other recorded design | 10 |
| No design recorded | 148 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 13 | |
| 2025 | 32 | |
| 2024 | 37 | |
| 2023 | 28 | |
| 2022 | 48 | |
| 2021 | 32 | |
| 2020 | 7 | |
| 2019 | 1 | |
| 2018 | 2 | |
| 2017 | 3 | |
| 2016 and earlier | 8 |
Other counts within the matched set
| Peer-reviewed articles | 203 |
| Marked open access in the record | 82 |
| Rated "high" evidence strength in alzhub's summary | 41 |
| Rated "moderate" evidence strength in alzhub's summary | 10 |
| Rated "low" evidence strength in alzhub's summary | 158 |
| No evidence-strength rating | 2 |
| Records stating a participant count | 22 |
| Median participants (those records) | 1,664 |
| Largest participant count | 23,202 |
Within the 211 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that also discuss ARIA | 86 | the abstract also contains "ARIA" or "amyloid-related imaging abnormalities" |
| …that also mention the FDA or regulatory approval | 72 | the abstract also contains "FDA", "regulator" or "accelerated approval" |
| …that also mention cost or price | 23 | the abstract also contains "cost" or "price" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease
- Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease
- CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab
- Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
- Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab
- Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
- Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis
- Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab
- Aducanumab for the treatment of Alzheimer's disease: a systematic review
Systematic reviews and meta-analyses in the set
14 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease
- Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
- The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials
- Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis
- Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
Newest matched studies
- Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis
- Brain-resident myeloid cells promote rapid leukocyte adhesion in leptomeningeal vessels after anti-Aβ immunotherapy
- Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease
- Therapeutic monoclonal antibodies targeting amyloid beta in Alzheimer disease current evidence clinical outcomes limitations and future directions
- Anti-amyloid immunotherapy drives APOE4 specific increases in glial reactivity, perivascular immune activation, and ARIA-like events
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 9 |
| The journal of prevention of Alzheimer's disease | 9 |
| Neurology | 8 |
| Ageing research reviews | 6 |
| Journal of Alzheimer's disease : JAD | 6 |
Questions
- Is aducanumab still available?
- Its manufacturer announced in 2024 that it was discontinuing the drug, so it is no longer marketed. The papers in the library document the trials, the approval and the debate.
- How many studies on aducanumab (aduhelm) does alzhub hold?
- 211 of the 29,380 study records in alzhub's library match the query "title or abstract mentions "aducanumab", "Aduhelm" or "BIIB037""; 84 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 14 systematic review or meta-analysis, 1 randomised controlled trial, 29 other clinical trials, 6 cohort or longitudinal studys, 1 case-control study, 2 cross-sectional studys; 148 record no design.
- What is the most recent study in the set?
- "Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis" (medRxiv (preprint), 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Alzheimer's & dementia : the journal of the Alzheimer's Association (9); The journal of prevention of Alzheimer's disease (9); Neurology (8), counted across the matched records.
Read on
- Anti-amyloid antibodies: what the trials showedAll three approved antibodies, with every figure sourced.
- TreatmentsApproved drugs, drugs in trials, and drugs that failed.